T-CURX announces $20M Series A first closing led by BiomedVC to fund pipeline of clinical-stage CAR-T programs and advance proprietary non-viral in vivo CAR-T platform

T-CURX GmbH (T-CURX) today announces the first closing of a $ 20M (€ 17.7M) Series A financing with a syndicate of European and Asian investors for accelerating clinical development of T-CURX non-viral clinical CAR-T therapies in AML and solid tumor indications, as well as advancing T-CURX proprietary non-viral technologies for in vivo CAR-T generation.

The Series A syndicate was led by BiomedVC and included Bayern Kapital, WuXi Biologics Healthcare Ventures, HighLight Capital (HLC), and i&iBio Fund, as additional investors along with existing and new individual investors.

Ulf Grawunder, PhD, co-founder and CEO of T-CURX, commented on the closing of this Series A financing round for T-CURX: “I am very excited that T-CURX attracted such a high-profile, international investor’s syndicate, led by BiomedVC, for financing T-CURX`s non-clinical and clinical CAR-T technologies and CAR-T pipeline programs, respectively. It is a testament of the high quality of T-CURX data and the promise of our non-clinical and clinical non-viral CAR-T pipeline in AML & CLL and solid tumor indications going after novel targets. It also highlights the high value of our unique approach to leverage non-viral CAR-vector and LNP technologies for highly economical and scalable in vivo CAR-T generation, in order to “democratize” CAR-T therapies for patients globally.”

Aristotelis Nastos, PhD, Managing Partner and investment director at lead-investor BiomedVC adds: “I am thrilled about leading a highly dedicated international syndicate of early-stage investors from Europe and Asia in this Series A financing for T-CURX. We were deeply impressed by the data on non-viral CAR-T product and technology development at T-CURX, the track-record and experience of T-CURX Founder’s and Management team and the promise of T-CURX non-viral CAR-T technolgies hold for making CAR-T therapies accessible and affordable for many cancer patients globally. We are very much looking forward to support T-CURX to achieve all of their therapeutic and commercial ambitions.”

T-CURX is a German Biotech company located in Würzburg and Munich, Germany,  spun-out of the laboratory of its co-founder, Prof. Michael Hudecek, University of Würzburg, who is a European KOL and pioneer in the development and clinical translation of non-viral CAR-T cell therapies to target various types of cancer.

About T-CURX

T-CURX is a privately owned, German Biotech company based in Würzburg founded in 2017 with the vision of bringing next-generation CAR-T cell therapies manufactured with cost-effective and highly scalable non-viral CAR-T cell technologies to more cancer patients in need of more effective cancer therapies. T-CURX was spun out of the laboratory of T-CURX co-founder Prof. Michael Hudecek at the University of Würzburg and is led by Ulf Grawunder, PhD, a seasoned serial entrepreneur as CEO, who is also one of the co-founders. T-CURX leverages a portfolio of proprietary non-viral CAR-T technologies for scalable and cost-effective CAR-T manufacturing based on virus-free, Sleeping-beauty transposon gene transfer into patient’s T cells. For more information about T-CURX visit the web-site www.t-curx.com.

About BiomedVC

BiomedVC is is a leading Swiss early-stage VC at the center of European biotech. BiomedVC builds companies around the most intriguing innovation. We strive to enable founders and their ideas. We work together on a basis of equality - as a team and with entrepreneurs. We focus on scientific excellence, building strong companies to create medical and commercial value and bring new medicines to market that improve patient’s lives.

About i&i Bio i&i Bio is a Luxembourg-based venture capital firm investing in innovative European life sciences companies specializing in drug discoveries, medical devices, diagnostics, and digital health. The fund, created through a collaboration between the biotech incubator i&i Prague and the European Investment Fund (EIF), manages over €53 million and aims to invest in approximately 20 early-stage companies. Led by a team with extensive experience in private equity, healthcare, and venture capital, i&i Bio supports entrepreneurs in achieving global success. The fund’s main sponsor, i&i Prague, plays a crucial role in advancing transformative Central European technology companies

The Fund is supported by an investment from the European Investment Fund (EIF), with the support of:

• lnnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing; and

• the Pan-European Guarantee Fund (EGF), implemented by the EIF with the financial support of the Participating Member States. The objective of EGF is to respond to the economic impact of the COVID-19 pandemic by ensuring that companies in the Participating Member States have sufficient short-term liquidity available to weather the crisis and are able to continue their growth and development in the medium to long-term.